Memorial Sloan Kettering Cancer Center published updates from an ongoing phase 1-2a study investigating the safety of ibrutinib in combination with nivolumab (Opdivo) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. The results were published in The Lancet Haematology. In this two-part, multicenter, open label, phase 1-2a study the appropriate dose (phase 1), as well as the safety and activity (phase 2a) of ibrutinib in combination with nivolumab were assessed in the following patient populations: R/R CLL/SLL with del17p or del11q (high-risk), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), or Richter’s transformation (RT). The primary aim of the phase 1 part of the study was to establish the appropriate treatment dose. The primary endpoint of the phase 2a part was to measure the preliminary efficacy of ibrutinib and nivolumab in the aforementioned patient populations, by assessing the proportion of patients achieving an overall response. Follow the link below to Ms. Sylvia Agathou’s article in Lymphoma Hub.